Evidence map›Paper›PMID 33237825›Full record

ArticleThe British journal of radiology2021

Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma.

Claire Timlin, James Loken, Jon Kruse, Robert Miller, Uwe Schneider

Open access · hybridAbstract read
In one paragraph

Article in The British journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Claire TimlinParticle Therapy Cancer Research Institute, University of Oxford, Oxford, UK.
James LokenParticle Therapy Cancer Research Institute, University of Oxford, Oxford, UK.
Jon KruseMayo Clinic, Rochester, MN, USA.
Robert MillerMayo Clinic, Rochester, MN, USA.
Uwe SchneiderDepartment of Physics, University of Zurich and Radiotherapy Hirslanden, Zurich, Switzerland.
Mayo Clinic in Arizona · USUniversity of Oxford · GBKlinik Hirslanden · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way.

methodsEAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties.

resultsParameter-driven uncertainties on total EAR are around 13%, decreasing to around 2-5% for relative EAR comparisons. Total EAR estimations indicate that intensity modulated proton therapy decreases the average risk by 40% compared to the intensity modulated radiation therapy plan, 28% compared to the volumetric modulated arc therapy plan whereas the three-dimensional conformal radiation therapy plan is equivalent within the uncertainty.

conclusionRelative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. ADVANCES IN KNOWLEDGE: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients.

Indexed as

Cancer SurvivorsHodgkin DiseaseHumansMonte Carlo MethodNeoplasms, Radiation-InducedNeoplasms, Second PrimaryProton TherapyRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRisk AssessmentTime FactorsUncertainty

Identifiers

PMID33237825
PMCPMC8506169
OpenAlexW3107412142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.